Cargando…

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Detalles Bibliográficos
Autores principales:	Tatham, Kate C., Shankar-Hari, Manu, Arabi, Yaseen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494625/ https://www.ncbi.nlm.nih.gov/pubmed/34617150 http://dx.doi.org/10.1007/s00134-021-06540-w

Ejemplares similares

Trials on oxygen supplementation in sepsis: better late than never
por: Perner, Anders, et al.
Publicado: (2019)

Immunological Subpopulations Within Critically Ill COVID-19 Patients
por: Wilson, Julie Kay, et al.
Publicado: (2021)

Scientific misconduct and medical publishing
por: Arabi, Yaseen M.
Publicado: (2007)

Toward evidence-based approach to deep venous thrombosis
por: Arabi, Yaseen M.
Publicado: (2015)

Predicting enteral feeding intolerance in patients with sepsis: Why and how?
por: Arabi, Yaseen M.
Publicado: (2022)

Use of Hydrocortisone Based on Plasma Biomarkers in Patients with Septic Shock: Another One Bites the Dust?
por: Møller, Morten Hylander, et al.
Publicado: (2020)

Do Nostrums Benefit Consumers?
Publicado: (1879)

Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials
por: Shankar-Hari, Manu, et al.
Publicado: (2020)

Physiologic role of interleukin-1 receptor antagonist
por: Arend, William P, et al.
Publicado: (2000)

Interleukin Expression after Injury and the Effects of Interleukin-1 Receptor Antagonist
por: Chamberlain, Connie S., et al.
Publicado: (2013)

Interleukin-1β and Interleukin-1 Receptor Antagonist Appear in Grey Matter Additionally to White Matter Lesions during Experimental Multiple Sclerosis
por: Prins, Marloes, et al.
Publicado: (2013)

The BENEFIT Trial: Where Do We Go from Here?
por: Pecoul, Bernard, et al.
Publicado: (2016)

The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse
por: Bjrök, P., et al.
Publicado: (1992)

If not now, when? A clinical perspective on the unprecedented challenges facing ICUs during the COVID-19 pandemic
por: Martin-Loeches, Ignacio, et al.
Publicado: (2021)

Targeting interleukin-17 receptors
por: Lee, Wen-Hwa, et al.
Publicado: (2015)

TILRR Steers Interleukin-1 Signaling: Co-Receptor Provides Context and a Therapeutic Target
por: Mac Gabhann, Feilim
Publicado: (2017)

Interleukin 1-β, Interleukin-1 Receptor Antagonist, and Interleukin 18 in Children with Acute Spontaneous Urticaria
por: Machura, E., et al.
Publicado: (2013)

Proceedings of the Middle East Respiratory Syndrome (MERS) Coronavirus research initiative workshop, September 9–10 2015 in Riyadh, KSA
por: Arabi, Yaseen M., et al.
Publicado: (2016)

Do patients benefit from platelet-rich plasma?
por: Atik, O. Şahap
Publicado: (2020)

Production of interleukin-1 receptor antagonist by human articular chondrocytes
por: Palmer, Gaby, et al.
Publicado: (2002)

Intracellular Function of Interleukin-1 Receptor Antagonist in Ischemic Cardiomyocytes
por: Vecile, Elena, et al.
Publicado: (2013)

Interleukin-1 Receptor Antagonist Isoforms in Collagen-Induced Arthritis
por: Gabay, Cem, et al.
Publicado: (2000)

Interleukin receptor antagonist induction in kidney transplantation: Is it worth the price?
por: Kher, V.
Publicado: (2013)

Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer
por: Gong, Zhenqiang, et al.
Publicado: (2018)

Roles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression
por: Fan, Yu-Ching, et al.
Publicado: (2020)

Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury
por: Lindblad, Caroline, et al.
Publicado: (2023)

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
por: Arabi, Yaseen M., et al.
Publicado: (2020)

The journey to zero deep-vein thrombosis in critically ill patients
por: Arabi, Yaseen M., et al.
Publicado: (2019)

How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis?
por: Shankar-Hari, M.
Publicado: (2017)

Registries: what level of evidence do they provide?
por: Roovers, Jan-Paul W. R.
Publicado: (2007)

Role of interleukin-25 in development of spontaneous arthritis in interleukin-1 receptor antagonist-deficient mice
por: Abe, Yasuharu, et al.
Publicado: (2017)

Splenectomy in sickle cell disease: do benefits outweigh risks?
por: Nardo-Marino, Amina, et al.
Publicado: (2022)

Why do antioxidants fail to provide clinical benefit?
por: Warnholtz, Ascan, et al.
Publicado: (2000)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Beyond Vasodilator: Anti-Apoptotic Effect of Endothelin Receptor Antagonist
por: Chang, Sung-A
Publicado: (2014)

Treating hot flushes with a neurokinin 3 receptor antagonist
por: Prague, Julia K., et al.
Publicado: (2017)

What do remote scientific meetings provide us?
por: Sakata, Yasushi
Publicado: (2021)

Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk
por: Lindmark, F, et al.
Publicado: (2005)

Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist
Publicado: (1995)

Arterial Inflammation in Mice Lacking the Interleukin 1 Receptor Antagonist Gene
por: Nicklin, Martin J.H., et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_1955jpl87cu3drtuo0i9rlbdnl